DrugPatentWatch Database Preview

ZEMDRI Drug Profile

« Back to Dashboard

When do Zemdri patents expire, and when can generic versions of Zemdri launch?

Zemdri is a drug marketed by Achaogen Inc and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

The generic ingredient in ZEMDRI is plazomicin sulfate. One supplier is listed for this compound. Additional details are available on the plazomicin sulfate profile page.

Summary for ZEMDRI

International Patents:	28
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Drug Prices:	Drug price information for ZEMDRI
Prior Art and Litigation Support	Order Prior Art and Litigation support for ZEMDRI
DailyMed Link:	ZEMDRI at DailyMed

Generic Entry Opportunity Date for ZEMDRI

NDA:

210303

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZEMDRI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Achaogen Inc	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes				Y
Achaogen Inc	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes			Y
Achaogen Inc	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes				Y

International Patents for ZEMDRI

Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	017824
Canada	2706369
Mexico	2010005632